Grifols' Talecris purchase hits snag; Antisense's trabedersen gets good Phase IIb news;

 @FierceBiotech: In bombshell, DOJ reverses stance on gene patents. Report | Follow @FierceBiotech

 @JohnCFierce: Glaxo inks $231M pact for Phase III Amicus drug. Another rare disease pact for the pharma giant. Article  | Follow @JohnCFierce

> The Federal Trade Commission will try to halt Grifols's $3.3 billion acquisition of Talecris Biotherapeutics Holdings. It's the second time the FTC has stopped a Talecris sale based on antitrust issues. Report

> German biopharmaceutical company Antisense Pharma has released results from its Phase IIb study of trabedersen on malignant brain tumors. The drug had a significant impact on two-year survival and response rates. Antisense release

> Zalicus received a $244,000 grant to continue developing its Phase II product candidate Synavive, a potential rheumatoid arthritis therapy. Zalicus release

> Hyperion Therapeutics' glycerol phenylbutyrate, a urea cycle disorder therapy, has met its primary endpoint in a Phase III study. The 4-week, 46 patient study was conducted in June 2009. Hyperion release

> Patients taking inhaled corticosteroids are at increased risk of developing Type 2 diabetes, and more so with higher doses. Release

And Finally... Illicit drugs' allure is no new news; an exhibit at London's Wellcome Collection looks back at the use, benefits and issues of hallucinogens, cannabis and even espresso coffee throughout history and culture. Article

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.